search
Back to results

Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window (Tension)

Primary Purpose

Stroke, Acute, Cerebral Stroke, Cerebrovascular Stroke

Status
Active
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Thrombectomy
Best medical care
Sponsored by
University Hospital Heidelberg
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stroke, Acute focused on measuring Mechanical thrombectomy, Endovascular thrombectomy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Randomization within 11 hours after stroke onset (if known) or last seen well.
  • Endovascular treatment is expected to be finished within 12 hours after known symptom onset or last seen well by judgment of the interventional neuroradiologist in charge (if stroke onset is known).
  • Patient must demonstrate clinical signs and symptoms attributable to target area of occlusion consistent with the diagnosis of ischemic stroke, including impairment of the following: language, motor function, sensation, cognition, gaze, and/or vision for at least 30 minutes without relevant improvement.
  • Female and male patient above 18 years of age
  • NIHSS Score of <26
  • Signed informed consent (IC) form by patient or legal guardian, or inclusion of patient's presumptive will by investigator under emergency situation, but after consultation of an independent physician who is familiar with these types of illness if the other options are not possible according to local approval.
  • Prior to new focal neurological deficit, mRS score was ≤2.

Imaging Inclusion Criteria

  • A new focal occlusion confirmed by imaging (MRA/CTA) to be accessible to the thrombectomy device, and located in the M1 of the middle cerebral artery (MCA) and/or the intracranial segment of the distal internal carotid artery (ICA).
  • CT (non-contrast CT) or DWI with an ASPECT score of 3-5

Clinical exclusion criteria

  • Patient is an active participant in another drug or device treatment trial for any disease state or patient is expected to start participation in another drug or device treatment trial while enrolled in this protocol, unless approved by Sponsor.
  • Patient has pre-existing neurological or psychiatric disease that could impede the study results or would confound the neurological or functional evaluations.
  • Patient has vascular disease preventing endovascular treatment (e.g. aortic dissection or aneurysm, no arterial transfemoral access)
  • Patient has history of contraindication for contrast medium.
  • Patient is known to have infective endocarditis
  • Patient's anticipated life expectancy is less than 6 Months12 months

Imaging exclusion criteria

  • ExtracaranialExtracranial CT scan or MR angiography showing high grade stenosis expected to require acute stent placement (especially e.g. ICAACI stenting) during the procedure to get access to the occlusion
  • CT or MRI with evidence of: Mass mass effect or intracranial tumor, or hypodensity on unenhanced CT and
  • If CT perfusion is done per institutional standard: CBV drop on CBV maps on CTP, or, alternatively as with an ASPECT score of 0-2
  • If DWI is done per institutional standard,: restricted diffusion on DWI with an ASPECT score of 0-2, or above 5

Sites / Locations

  • Division of Neuroradiology, Vascular and Interventional Radiology, Department of Radiology, Medical University Graz
  • Medical University Innsbruck
  • Neuroradiology, Keppler University Hospital Linz
  • Department of Neurology, Reseach Institute of Neurointervention, Christian Doppler Clinic, Paracelsus Medical University Salzburg
  • University of Calgary
  • St. Anne's University Hospital Brno
  • Faculty Hospital Hradec Kralove
  • Comprehensive stroke center,University Hospital Ostrava
  • Homolka Hospital Prague
  • Dept. of Radiology, Masaryk hospital
  • Aalborg University Hospital
  • Aarhus University Hospital
  • University Hospital Rigshospitalet
  • CHU Gabriel Montpied, Clermont-Ferrand
  • Hôpiteaux Universitaires Paris-Sud, Hôpital Bicêtre
  • Hôpital Pitié-Salpêtrière
  • Université Reims Champagne Ardenne/ Department of Neuroradiology, Hôpital Maison Blanche
  • CHU de Rennes/Centre Urgences-Réanimations
  • CHRU Hôpiteaux de Tours / Hôpital Bretonneau
  • Universitätsinstitut für Diagnostische Radiologie, Neuroradiologie und Nuklearmedizin Johannes Wesling Klinikum Minden
  • Otto-von-Guericke-University Magdeburg
  • Universitätsklinikum KK Bochum-Langendreer Institut für Diagnostische und Interventionelle Radiologie, Neuroradiologie und Nuklearmedizin
  • Universitätsklinikum Bonn
  • Gesundheit Nord gGmbH Klinikverbund Bremen
  • Klinik für Radiologie und Neuroradiologie am Klinikum Mitte
  • Universitätsklinikum Carl Gustav Carus Dresden
  • Alfried Krupp Krankenhaus Rüttenscheid
  • Diakonissenkrankenhaus Flensburg
  • Universitätsklinikum Hamburg-Eppendorf
  • Neuroradiologie Universitätsklinikum Heidelberg
  • Universitätsklinikum Leipzig AöR
  • UKSH Universitätsklinikum Schleswig-Holstein Campus Lübeck
  • Klinikum der Universität München
  • Technische Universität München / Klinikum rechts der Isar
  • Universitätsklinikum Würzburg
  • Haukeland University Hospital
  • Oslo University Hospital
  • The Arctic University of Norway
  • Comenius University's Jessenius Faculty of Medicine and University Hospital
  • Faculty Hospital Trnava
  • La Paz University Hospital
  • University Hospital Basel

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Other

Arm Label

Thrombectomy

Best medical care

Arm Description

Endovascular thrombectomy and best medical care

Best medical treatment

Outcomes

Primary Outcome Measures

Clinical outcome-modified Rankin Scale at 90 days
The primary endpoint of the trial is the modified Rankin Scale (mRS) outcome at 90 days post-stroke. The primary effectiveness endpoint analysis is a chi-square test of the difference in linear trends in ordinal mRS outcomes at 90 days post-procedure between treatment groups ("mRS shift analysis").

Secondary Outcome Measures

Independence - modified Rankin Scale≤2 at 90 days
Independent neurological outcomes with 90-day mRS≤2
Moderate Outcome - modified Rankin Scale≤3 at 90 days
Moderate neurological outcome with 90-day mRS≤3
Infarct volume 24 hours post procedure
Infarct volume at 24 hours on post-procedure imaging
Infarct growth
Difference of infarct volume from infarct volume as predicted by pre-treatment imaging
Functional neurological outcome at 12 months - modified Rankin Scale
Functional neurological outcome at 12 months (±14 days) after stroke (simplified modified Rankin Scale questionnaire, smRSq)
Quality of life - PROMIS-10
Patient-Reported Outcomes Measurement Information System (PROMIS)-10 questionaire at 90 (±14) days. PROMIS Global-10 short form consists of 10 items that assess general domains of health and functioning including overall physical health, mental health, social health, pain, fatigue, and overall perceived quality of life.
Quality of life - EQ-5D
Patient-reported functional health status and quality of life 90 (±14) days. EuroQol five-dimension scale. A standardised instrument created by the EuroQol Group as a measure of health outcome. EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each of which can take one of three responses reflecting severity (no problems/some or moderate problems/extreme problems).
Post-stroke depression - Patient Health Questionnaire-4
Post-stroke depression 90 (±14) days after stroke based on the Patient Health Questionnaire-4 (PHQ-4), Patient Health Questionnaire-4, Psychological distress in PHQ-4 is being rated based on 4 questions as none (0-2") mild (3-5) moderate (6-8) severe (9-12)
Parenchymal hemorrhage type 2
blood clots in >30% of the infarcted area with a substantial space-occupying effect.
modified Rankin Scale between 4-6
Death or dependency
Frequencies of Adverse Events (AE) in both treatment arms within the first 7 days
Serious AEs (SAEs), overall (all-cause mortality) and stroke-related death (i.e., related to intracranial bleeding, midline shift, brain herniation, progression of stroke symptoms, or systemic complications from stroke such as pneumonia). Space-occupying infarction (malignant brain edema) New ischemic stroke
Serious AEs
Serious AEs (SAEs), overall (all-cause mortality) and stroke-related death (i.e., related to intracranial bleeding, midline shift, brain herniation, progression of stroke symptoms, or systemic complications from stroke such as pneumonia).
Space-occupying infarction
Malignant brain edema after treatment
New ischemic stroke
New AIS after treatment
Symptomatic intracranial hemorrhage (sICH) at 24 (18-36) hours (CT or MRI)
sICH as defined in Safe Implementation of Treatments in Stroke-Monitoring Study (SITS-MOST) parenchymal hemorrhage type 2 (PH-2) Frequencies of Adverse Events (AE) in both treatment arms within the first 7 days after treatment Serious AEs (SAEs), overall (all-cause mortality) and stroke-related death (i.e., related to intracranial bleeding, midline shift, brain herniation, progression of stroke symptoms, or systemic complications from stroke such as pneumonia). Space-occupying infarction (malignant brain edema) New ischemic stroke
Cost Utility Assessment
Assessment of costs from the time of randomization to the 12-months follow-up, including costs of hospitalization, institutionalized living, outpatient care, informal care provided by relatives and cost of lost productivity
Quality of life - PROMIS-10
Patient-Reported Outcomes Measurement Information System (PROMIS)-10 questionaire at 12 month (±14 days). PROMIS Global-10 short form consists of 10 items that assess general domains of health and functioning including overall physical health, mental health, social health, pain, fatigue, and overall perceived quality of life.
Quality of life - EQ-5D
Health related quality of life assessment at 12 months (±14 days). EuroQol five-dimension scale. A standardised instrument created by the EuroQol Group as a measure of health outcome. EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each of which can take one of three responses reflecting severity (no problems/some or moderate problems/extreme problems).
Post-stroke depression - Patient Health Questionnaire-4
Health related quality of life assessment at 12 months (±14 days) to assess post stroke depression - Patient Health Questionnaire-4 (PHQ-4) Psychological distress in PHQ-4 is being rated based on 4 questions as none (0-2") mild (3-5) moderate (6-8) severe (9-12)

Full Information

First Posted
March 16, 2017
Last Updated
April 3, 2023
Sponsor
University Hospital Heidelberg
Collaborators
Karolinska University Hospital, Eppdata GmbH Hamburg, Germany, Aarhus University Hospital, Medical University Innsbruck, Groupe Hospitalier Pitie-Salpetriere, Oslo University Hospital, University Hospital, Martin, Charles University, Czech Republic, Hospices Civils de Lyon, CHU de Reims, Epidemiological and Clinical Research Information Network, STROKE ALLIANCE FOR EUROPE, International Consortium for Health Outcome Measurement, Inc., Europan Society for Minimally Invasive Neurological Therapy, Universitätsklinikum Hamburg-Eppendorf
search

1. Study Identification

Unique Protocol Identification Number
NCT03094715
Brief Title
Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window
Acronym
Tension
Official Title
Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window: a Randomized, Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
June 20, 2018 (Actual)
Primary Completion Date
May 31, 2023 (Anticipated)
Study Completion Date
November 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospital Heidelberg
Collaborators
Karolinska University Hospital, Eppdata GmbH Hamburg, Germany, Aarhus University Hospital, Medical University Innsbruck, Groupe Hospitalier Pitie-Salpetriere, Oslo University Hospital, University Hospital, Martin, Charles University, Czech Republic, Hospices Civils de Lyon, CHU de Reims, Epidemiological and Clinical Research Information Network, STROKE ALLIANCE FOR EUROPE, International Consortium for Health Outcome Measurement, Inc., Europan Society for Minimally Invasive Neurological Therapy, Universitätsklinikum Hamburg-Eppendorf

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
TENSION (Efficacy and safety of ThrombEctomy iN Stroke with extended leSION and extended time window) is a prospective, open label, blinded endpoint (PROBE), European two-arm, randomized, controlled, post-market study to compare the safety and effectiveness of endovascular thrombectomy as compared to best medical care alone in the treatment of acute ischemic stroke patients with extended stroke lesions defined by an Alberta Stroke Program Early CT Score (ASPECTS) score of 3-5 and in an extended time window (up to 12 hours or unknown time of symptom onset). Up to 665 subjects will be randomized. Primary endpoint will be functional outcome assessed by the modified Rankin scale at 90 days post-stroke ("mRS shift analysis"). By this, TENSION will provide evidence of efficacy and safety of thrombectomy in an acute stroke population with uncertain benefit of endovascular stroke treatment.
Detailed Description
This study is a prospective, open label, blinded endpoint (PROBE),European, two-arm, randomized, controlled, post-market study to compare the safety and effectiveness of endovascular thrombectomy as compared to best medical care alone in the treatment of acute ischemic stroke (AIS) in patients with extended stroke lesions defined by an ASPECT score of 3-5 and in an extended time window (up to 12 hours, or unknown time of symptom onset). This is an adaptive design study, with prospectively stated interim analyses with specified stopping rules allowing for the possibility early termination based on either a determination of study success or futility. Up to 665 subjects will be enrolled in the study and randomized for the Intention to treat analysis set. The randomization will be stratified by time from symptom onset (0-6h and 6-11h/wake up stroke), and stroke severity (NIHSS ≤18, NIHSS >18). Interim data analysis is planned after the primary endpoint has been obtained for one third and two thirds of the patients. At each of these sample sizes, the available 90-day mRS data for each treatment arm will be evaluated. Safety interim analysis will be performed after one third and two thirds of the patients have been included. Subjects who meet the inclusion criteria will be randomized in a 1:1 ratio to one of the following two treatment arms: Arm 1: best medical care Arm 2: endovascular thrombectomy and best medical care The primary objective of this study is to test efficacy and safety of thrombectomy in acute stroke patients with uncertain benefit of endovascular stroke treatment, i.e. extended ischemic lesion size with an ASPECT score of 3-5 or late (up to 12 hours) or unknown time window as compared to best medical care alone. Approximately 40 sites in Up to 20 sites in 8-10 European countries Patients presenting with acute ischemic stroke (AIS) based on focal occlusion in the M1 segment of the middle cerebral artery (MCA), and/or the intracranial segment of the distal internal carotid artery (ICA), determined by Magnetic Resonance Angiography (MRA) or Computed Tomographic Angiography (CTA), and who meet all eligibility criteria will be considered for study enrollment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke, Acute, Cerebral Stroke, Cerebrovascular Stroke, Apoplexy; Brain
Keywords
Mechanical thrombectomy, Endovascular thrombectomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
prospective, open label, blinded endpoint (PROBE), European, two-arm, randomized, controlled, post-market study
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
253 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Thrombectomy
Arm Type
Active Comparator
Arm Description
Endovascular thrombectomy and best medical care
Arm Title
Best medical care
Arm Type
Other
Arm Description
Best medical treatment
Intervention Type
Device
Intervention Name(s)
Thrombectomy
Other Intervention Name(s)
Mechanical thrombectomy
Intervention Description
Mechanical thrombectomy with state of the art thrombectomy devices (i.e. stent-retrievers, aspiration catheters). Devices will be used per instructions for use (IFU).
Intervention Type
Other
Intervention Name(s)
Best medical care
Other Intervention Name(s)
Control group
Intervention Description
Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.). If applicable, the reason for iv tissue plasminogen activator (tPA) ineligibility has to be documented on the eCRF.
Primary Outcome Measure Information:
Title
Clinical outcome-modified Rankin Scale at 90 days
Description
The primary endpoint of the trial is the modified Rankin Scale (mRS) outcome at 90 days post-stroke. The primary effectiveness endpoint analysis is a chi-square test of the difference in linear trends in ordinal mRS outcomes at 90 days post-procedure between treatment groups ("mRS shift analysis").
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Independence - modified Rankin Scale≤2 at 90 days
Description
Independent neurological outcomes with 90-day mRS≤2
Time Frame
90 days
Title
Moderate Outcome - modified Rankin Scale≤3 at 90 days
Description
Moderate neurological outcome with 90-day mRS≤3
Time Frame
90 days
Title
Infarct volume 24 hours post procedure
Description
Infarct volume at 24 hours on post-procedure imaging
Time Frame
18-36 hours
Title
Infarct growth
Description
Difference of infarct volume from infarct volume as predicted by pre-treatment imaging
Time Frame
18-36 hours
Title
Functional neurological outcome at 12 months - modified Rankin Scale
Description
Functional neurological outcome at 12 months (±14 days) after stroke (simplified modified Rankin Scale questionnaire, smRSq)
Time Frame
12 month
Title
Quality of life - PROMIS-10
Description
Patient-Reported Outcomes Measurement Information System (PROMIS)-10 questionaire at 90 (±14) days. PROMIS Global-10 short form consists of 10 items that assess general domains of health and functioning including overall physical health, mental health, social health, pain, fatigue, and overall perceived quality of life.
Time Frame
90 days
Title
Quality of life - EQ-5D
Description
Patient-reported functional health status and quality of life 90 (±14) days. EuroQol five-dimension scale. A standardised instrument created by the EuroQol Group as a measure of health outcome. EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each of which can take one of three responses reflecting severity (no problems/some or moderate problems/extreme problems).
Time Frame
90 days
Title
Post-stroke depression - Patient Health Questionnaire-4
Description
Post-stroke depression 90 (±14) days after stroke based on the Patient Health Questionnaire-4 (PHQ-4), Patient Health Questionnaire-4, Psychological distress in PHQ-4 is being rated based on 4 questions as none (0-2") mild (3-5) moderate (6-8) severe (9-12)
Time Frame
90 days
Title
Parenchymal hemorrhage type 2
Description
blood clots in >30% of the infarcted area with a substantial space-occupying effect.
Time Frame
90 days
Title
modified Rankin Scale between 4-6
Description
Death or dependency
Time Frame
12 month
Title
Frequencies of Adverse Events (AE) in both treatment arms within the first 7 days
Description
Serious AEs (SAEs), overall (all-cause mortality) and stroke-related death (i.e., related to intracranial bleeding, midline shift, brain herniation, progression of stroke symptoms, or systemic complications from stroke such as pneumonia). Space-occupying infarction (malignant brain edema) New ischemic stroke
Time Frame
7 days
Title
Serious AEs
Description
Serious AEs (SAEs), overall (all-cause mortality) and stroke-related death (i.e., related to intracranial bleeding, midline shift, brain herniation, progression of stroke symptoms, or systemic complications from stroke such as pneumonia).
Time Frame
12 month
Title
Space-occupying infarction
Description
Malignant brain edema after treatment
Time Frame
18-36 hours
Title
New ischemic stroke
Description
New AIS after treatment
Time Frame
12 month
Title
Symptomatic intracranial hemorrhage (sICH) at 24 (18-36) hours (CT or MRI)
Description
sICH as defined in Safe Implementation of Treatments in Stroke-Monitoring Study (SITS-MOST) parenchymal hemorrhage type 2 (PH-2) Frequencies of Adverse Events (AE) in both treatment arms within the first 7 days after treatment Serious AEs (SAEs), overall (all-cause mortality) and stroke-related death (i.e., related to intracranial bleeding, midline shift, brain herniation, progression of stroke symptoms, or systemic complications from stroke such as pneumonia). Space-occupying infarction (malignant brain edema) New ischemic stroke
Time Frame
18-36 hours
Title
Cost Utility Assessment
Description
Assessment of costs from the time of randomization to the 12-months follow-up, including costs of hospitalization, institutionalized living, outpatient care, informal care provided by relatives and cost of lost productivity
Time Frame
12 month
Title
Quality of life - PROMIS-10
Description
Patient-Reported Outcomes Measurement Information System (PROMIS)-10 questionaire at 12 month (±14 days). PROMIS Global-10 short form consists of 10 items that assess general domains of health and functioning including overall physical health, mental health, social health, pain, fatigue, and overall perceived quality of life.
Time Frame
12 month
Title
Quality of life - EQ-5D
Description
Health related quality of life assessment at 12 months (±14 days). EuroQol five-dimension scale. A standardised instrument created by the EuroQol Group as a measure of health outcome. EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each of which can take one of three responses reflecting severity (no problems/some or moderate problems/extreme problems).
Time Frame
12 month
Title
Post-stroke depression - Patient Health Questionnaire-4
Description
Health related quality of life assessment at 12 months (±14 days) to assess post stroke depression - Patient Health Questionnaire-4 (PHQ-4) Psychological distress in PHQ-4 is being rated based on 4 questions as none (0-2") mild (3-5) moderate (6-8) severe (9-12)
Time Frame
12 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Randomization within 11 hours after stroke onset (if known) or last seen well. Endovascular treatment is expected to be finished within 12 hours after known symptom onset or last seen well by judgment of the interventional neuroradiologist in charge (if stroke onset is known). Patient must demonstrate clinical signs and symptoms attributable to target area of occlusion consistent with the diagnosis of ischemic stroke, including impairment of the following: language, motor function, sensation, cognition, gaze, and/or vision for at least 30 minutes without relevant improvement. Female and male patient above 18 years of age NIHSS Score of <26 Signed informed consent (IC) form by patient or legal guardian, or inclusion of patient's presumptive will by investigator under emergency situation, but after consultation of an independent physician who is familiar with these types of illness if the other options are not possible according to local approval. Prior to new focal neurological deficit, mRS score was ≤2. Imaging Inclusion Criteria A new focal occlusion confirmed by imaging (MRA/CTA) to be accessible to the thrombectomy device, and located in the M1 of the middle cerebral artery (MCA) and/or the intracranial segment of the distal internal carotid artery (ICA). CT (non-contrast CT) or DWI with an ASPECT score of 3-5 Clinical exclusion criteria Patient is an active participant in another drug or device treatment trial for any disease state or patient is expected to start participation in another drug or device treatment trial while enrolled in this protocol, unless approved by Sponsor. Patient has pre-existing neurological or psychiatric disease that could impede the study results or would confound the neurological or functional evaluations. Patient has vascular disease preventing endovascular treatment (e.g. aortic dissection or aneurysm, no arterial transfemoral access) Patient has history of contraindication for contrast medium. Patient is known to have infective endocarditis Patient's anticipated life expectancy is less than 6 Months12 months Imaging exclusion criteria ExtracaranialExtracranial CT scan or MR angiography showing high grade stenosis expected to require acute stent placement (especially e.g. ICAACI stenting) during the procedure to get access to the occlusion CT or MRI with evidence of: Mass mass effect or intracranial tumor, or hypodensity on unenhanced CT and If CT perfusion is done per institutional standard: CBV drop on CBV maps on CTP, or, alternatively as with an ASPECT score of 0-2 If DWI is done per institutional standard,: restricted diffusion on DWI with an ASPECT score of 0-2, or above 5
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Götz Thomalla, MD
Organizational Affiliation
Coordination and Project Management Tension, Neurology, UKE Hamburg, Germany
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Martin Bendszus, MD
Organizational Affiliation
Central Trial Management Tension, Neuroradiology, UHHeidelberg, Germany
Official's Role
Principal Investigator
Facility Information:
Facility Name
Division of Neuroradiology, Vascular and Interventional Radiology, Department of Radiology, Medical University Graz
City
Graz
ZIP/Postal Code
8036
Country
Austria
Facility Name
Medical University Innsbruck
City
Innsbruck
ZIP/Postal Code
6020
Country
Austria
Facility Name
Neuroradiology, Keppler University Hospital Linz
City
Linz
ZIP/Postal Code
4020
Country
Austria
Facility Name
Department of Neurology, Reseach Institute of Neurointervention, Christian Doppler Clinic, Paracelsus Medical University Salzburg
City
Salzburg
ZIP/Postal Code
5020
Country
Austria
Facility Name
University of Calgary
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N 1N4
Country
Canada
Facility Name
St. Anne's University Hospital Brno
City
Brno
ZIP/Postal Code
65691
Country
Czechia
Facility Name
Faculty Hospital Hradec Kralove
City
Hradec Kralove,
ZIP/Postal Code
50005
Country
Czechia
Facility Name
Comprehensive stroke center,University Hospital Ostrava
City
Ostrava
ZIP/Postal Code
70852
Country
Czechia
Facility Name
Homolka Hospital Prague
City
Prague
ZIP/Postal Code
150 30
Country
Czechia
Facility Name
Dept. of Radiology, Masaryk hospital
City
Usti nad Labem
ZIP/Postal Code
40003
Country
Czechia
Facility Name
Aalborg University Hospital
City
Aalborg
ZIP/Postal Code
9000
Country
Denmark
Facility Name
Aarhus University Hospital
City
Aarhus
ZIP/Postal Code
8000
Country
Denmark
Facility Name
University Hospital Rigshospitalet
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark
Facility Name
CHU Gabriel Montpied, Clermont-Ferrand
City
Clermont-Ferrand
ZIP/Postal Code
63000
Country
France
Facility Name
Hôpiteaux Universitaires Paris-Sud, Hôpital Bicêtre
City
Le Kremlin-Bicêtre
ZIP/Postal Code
94270
Country
France
Facility Name
Hôpital Pitié-Salpêtrière
City
Paris
ZIP/Postal Code
75013
Country
France
Facility Name
Université Reims Champagne Ardenne/ Department of Neuroradiology, Hôpital Maison Blanche
City
Reims
ZIP/Postal Code
51100
Country
France
Facility Name
CHU de Rennes/Centre Urgences-Réanimations
City
Rennes
ZIP/Postal Code
35033
Country
France
Facility Name
CHRU Hôpiteaux de Tours / Hôpital Bretonneau
City
Tours
ZIP/Postal Code
37044
Country
France
Facility Name
Universitätsinstitut für Diagnostische Radiologie, Neuroradiologie und Nuklearmedizin Johannes Wesling Klinikum Minden
City
Minden
State/Province
Nordrhein-Westfalen
ZIP/Postal Code
32429
Country
Germany
Facility Name
Otto-von-Guericke-University Magdeburg
City
Magdeburg
State/Province
Sachsen-Anhalt
ZIP/Postal Code
39120
Country
Germany
Facility Name
Universitätsklinikum KK Bochum-Langendreer Institut für Diagnostische und Interventionelle Radiologie, Neuroradiologie und Nuklearmedizin
City
Bochum
ZIP/Postal Code
44892
Country
Germany
Facility Name
Universitätsklinikum Bonn
City
Bonn
ZIP/Postal Code
53127
Country
Germany
Facility Name
Gesundheit Nord gGmbH Klinikverbund Bremen
City
Bremen
ZIP/Postal Code
28211
Country
Germany
Facility Name
Klinik für Radiologie und Neuroradiologie am Klinikum Mitte
City
Dortmund
ZIP/Postal Code
44137
Country
Germany
Facility Name
Universitätsklinikum Carl Gustav Carus Dresden
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Facility Name
Alfried Krupp Krankenhaus Rüttenscheid
City
Essen
ZIP/Postal Code
45131
Country
Germany
Facility Name
Diakonissenkrankenhaus Flensburg
City
Flensburg
ZIP/Postal Code
24939
Country
Germany
Facility Name
Universitätsklinikum Hamburg-Eppendorf
City
Hamburg
ZIP/Postal Code
20251
Country
Germany
Facility Name
Neuroradiologie Universitätsklinikum Heidelberg
City
Heidelberg
ZIP/Postal Code
69120
Country
Germany
Facility Name
Universitätsklinikum Leipzig AöR
City
Leipzig
ZIP/Postal Code
04103
Country
Germany
Facility Name
UKSH Universitätsklinikum Schleswig-Holstein Campus Lübeck
City
Lübeck
ZIP/Postal Code
23538
Country
Germany
Facility Name
Klinikum der Universität München
City
München
ZIP/Postal Code
81377
Country
Germany
Facility Name
Technische Universität München / Klinikum rechts der Isar
City
München
ZIP/Postal Code
81675
Country
Germany
Facility Name
Universitätsklinikum Würzburg
City
Würzburg
ZIP/Postal Code
97080
Country
Germany
Facility Name
Haukeland University Hospital
City
Bergen
ZIP/Postal Code
5021
Country
Norway
Facility Name
Oslo University Hospital
City
Oslo
ZIP/Postal Code
NO-0407
Country
Norway
Facility Name
The Arctic University of Norway
City
Tromsø
ZIP/Postal Code
9038
Country
Norway
Facility Name
Comenius University's Jessenius Faculty of Medicine and University Hospital
City
Martin
ZIP/Postal Code
03659
Country
Slovakia
Facility Name
Faculty Hospital Trnava
City
Trnava
ZIP/Postal Code
91775
Country
Slovakia
Facility Name
La Paz University Hospital
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Facility Name
University Hospital Basel
City
Basel
ZIP/Postal Code
CH-4031
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing URL
https://tension-study.com
Citations:
PubMed Identifier
34125952
Citation
Roaldsen MB, Jusufovic M, Berge E, Lindekleiv H. Endovascular thrombectomy and intra-arterial interventions for acute ischaemic stroke. Cochrane Database Syst Rev. 2021 Jun 14;6(6):CD007574. doi: 10.1002/14651858.CD007574.pub3.
Results Reference
derived
PubMed Identifier
30156479
Citation
Bendszus M, Bonekamp S, Berge E, Boutitie F, Brouwer P, Gizewski E, Krajina A, Pierot L, Randall G, Simonsen CZ, Zelenak K, Fiehler J, Thomalla G. A randomized controlled trial to test efficacy and safety of thrombectomy in stroke with extended lesion and extended time window. Int J Stroke. 2019 Jan;14(1):87-93. doi: 10.1177/1747493018798558. Epub 2018 Aug 29.
Results Reference
derived

Learn more about this trial

Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window

We'll reach out to this number within 24 hrs